Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

Contributed by: PR Newswire

Tags

LUNDBECK-Vyepti-auth

More Like This

Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine

Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine